These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10625946)

  • 1. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment.
    Grases F; Costa-Bauzá A
    Anticancer Res; 1999; 19(5A):3717-22. PubMed ID: 10625946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A
    Arch Esp Urol; 1999; 52(1):94-9. PubMed ID: 10101897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A; Grases F; Costa-Bauzá A; Prieto RM
    Arch Esp Urol; 1999 Apr; 52(3):305-10. PubMed ID: 10371752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of inositol hexaphosphate (phytate) on calcium binding, calcium oxalate crystallization and in vitro stone growth.
    Saw NK; Chow K; Rao PN; Kavanagh JP
    J Urol; 2007 Jun; 177(6):2366-70. PubMed ID: 17509360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis.
    Grases F; Perelló J; Isern B; Prieto RM
    Br J Dermatol; 2005 May; 152(5):1022-5. PubMed ID: 15888163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key Aspects of Myo-Inositol Hexaphosphate (Phytate) and Pathological Calcifications.
    Grases F; Costa-Bauza A
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31817119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting the regrowth of renal stones in vitro: a contribution to the understanding of renal stone development.
    Costa-Bauzá A; Isern B; Perelló J; Sanchis P; Grases F
    Scand J Urol Nephrol; 2005; 39(3):194-9. PubMed ID: 16118089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary phytate in calcium oxalate stone formers and healthy people--dietary effects on phytate excretion.
    Grases F; March JG; Prieto RM; Simonet BM; Costa-Bauzá A; García-Raja A; Conte A
    Scand J Urol Nephrol; 2000 Jun; 34(3):162-4. PubMed ID: 10961468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats.
    Grases F; Perelló J; Prieto RM; Simonet BM; Torres JJ
    Life Sci; 2004 May; 75(1):11-9. PubMed ID: 15102518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates.
    Grases F; Ramis M; Costa-Bauzá A
    Urol Res; 2000 Apr; 28(2):136-40. PubMed ID: 10850638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Mixtures of Magnesium, Citrate and Phytate as Calcium Oxalate Crystallization Inhibitors in Urine.
    Grases F; Rodriguez A; Costa-Bauza A
    J Urol; 2015 Sep; 194(3):812-9. PubMed ID: 25818031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phytate acts as an inhibitor in formation of renal calculi.
    Grases F; Isern B; Sanchis P; Perello J; Torres JJ; Costa-Bauza A
    Front Biosci; 2007 Jan; 12():2580-7. PubMed ID: 17127264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
    Costa-Bauzá A; Perelló J; Isern B; Sanchis P; Grases F
    BMC Urol; 2006 Jul; 6():16. PubMed ID: 16822299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phytate Dephosphorylation Products Also Act as Potent Inhibitors of Calcium Oxalate Crystallization.
    Grases F; Costa-Bauzá A; Calvó P; Julià F; Dietrich J; Gomila RM; Martorell G; Sanchis P
    Molecules; 2022 Aug; 27(17):. PubMed ID: 36080228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phytate inhibits bovine pericardium calcification in vitro.
    Grases F; Sanchis P; Costa-Bauzá A; Bonnin O; Isern B; Perelló J; Prieto RM
    Cardiovasc Pathol; 2008; 17(3):139-45. PubMed ID: 18402805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plant phosphates, phytate and pathological calcifications in chronic kidney disease.
    Buades Fuster JM; Sanchís Cortés P; Perelló Bestard J; Grases Freixedas F
    Nefrologia; 2017; 37(1):20-28. PubMed ID: 27697413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Phytate (InsP6) and Other Inositol-Phosphates (InsP5, InsP4, InsP3, InsP2) on Crystallization of Calcium Oxalate, Brushite, and Hydroxyapatite.
    Calvó P; Costa-Bauza A; Grases F
    Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uric acid as inducer of calcium oxalate crystal development.
    Grases F; Sanchis P; Isern B; Perelló J; Costa-Bauzá A
    Scand J Urol Nephrol; 2007; 41(1):26-31. PubMed ID: 17366099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Potential Relationship Between Phytate Ingestion, Urinary Phytate Excretion, and Renal Stone Risk in a Unique Human Model: No Hard Evidence in Support of Phytate as a Stone Inhibitor.
    Fakier S; Rodgers A
    J Ren Nutr; 2020 Sep; 30(5):396-403. PubMed ID: 31928801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inositol hexaphosphate (IP6) as an anti-neoplastic and lipid-lowering agent.
    Jariwalla RJ
    Anticancer Res; 1999; 19(5A):3699-702. PubMed ID: 10625943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.